Skip to main content
Clinical Trials/NCT02230449
NCT02230449
Completed
Not Applicable

Identifying Markers of Oocyte Competence Through a Maturation Analysis

Memorial Sisli Hospital, Istanbul1 site in 1 country200 target enrollmentAugust 2014
ConditionsInfertility

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Infertility
Sponsor
Memorial Sisli Hospital, Istanbul
Enrollment
200
Locations
1
Primary Endpoint
Cumulus cell RNA expression correlation with blastocyst formation potential and quality
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

The aim of the study is to analyze the expression of genes and microRNAs potentially involved in oocyte competence in follicles of different sizes (<17mm and ≥17mm) at the time of oocyte pick-up.

Detailed Description

In ART, one of the major obstacles encountered in some patients is the wide variation in the follicular size at the oocyte pick-up day and consequently, the number of available mature oocytes and the number of competent embryos for implantation. The follicular size at the day of oocyte pick-up reflects the synchronicity of the individual follicular responsiveness to FSH. For successful preimplantation development of an embryo, the oocyte must contain all necessary maternal factors. Two of these factors are specific mRNA transcripts (GDF9, PTX3, HAS2, PTGS2, TNFAIP6) and microRNA (miR-224). For each Cumulus Oocyte Complex, the evaluation of embryo development and morphokinetics will be correlated with the expression and implantation data to identify a quantitative biomarker to predict the embryo with the highest chance of implantation in patients. Experimental Design: 1. - Collection of Cumulus Oocyte Complex (COC) from patients 2. - Separation of oocytes according to the size of the follicule they have been retrieved from (\<17mm; ≥17mm) 3. - Isolation of mRNA from both groups of cumulus cells 4. - Expression studies, qRT-PCR (GDF9, PTX3, HAS2, PTGS2, TNFAIP6) 5. - Analysis of miR-224, a negative regulator of cumulus expansion via PTX3 6. - Time-lapse culture \& evaluation of morphokinetics

Registry
clinicaltrials.gov
Start Date
August 2014
End Date
September 2016
Last Updated
8 years ago
Study Type
Observational
Sex
Female

Investigators

Sponsor
Memorial Sisli Hospital, Istanbul
Responsible Party
Principal Investigator
Principal Investigator

Prof. Dr. Semra Kahraman

Director of ART and Genetics Center

Memorial Sisli Hospital, Istanbul

Eligibility Criteria

Inclusion Criteria

  • No more than 2 previous treatment cycles
  • No history of recurrent spontaneous abortions
  • Age ≤ 39 years
  • BMI \< 30 kg / m2
  • ≥ 8 cumulus-oocyte-complexes (COC) retrieved
  • human Chorionic Gonadotrophin (hCG) triggering

Exclusion Criteria

  • Preimplantaion Genetic Diagnosis (PGD) or Preimplantation Genetics Screening (PGS) indication
  • Maximum number of 24 COC during pickup
  • Failure to culture until Day 5
  • Polycystic ovary syndrome
  • Severe endometrial factor that can influence implantation
  • Uterine malformation or congenital anomaly
  • Severe male factor (Azoospermia)

Outcomes

Primary Outcomes

Cumulus cell RNA expression correlation with blastocyst formation potential and quality

Time Frame: 6 days

At the day of oocyte pick-up, cumulus cells will be collected from each cumulus oocyte complex. RNA extraction will be performed from those cumulus cells and expression levels of 5 genes and 1 miRNA will be measured (compared with that of a housekeeping gene). Oocytes of those samples will be injected and cultured with routine Assisted Reproduction Techniques. At the day 5 \& 6, after the oocyte pick-up procedure, each blastocyst formed will be noted and the quality of each blastocyst will be recorded. The blastocyst grading will be done according to Gardner's blastocyst morphological criteria (degree of expansion of the blastocoele cavity: 1 to 5, inner cell mass morphology: A to C, trophectoderm morphology: A to C). The composite primary outcome measure will allow the correlation of the expression levels of 5 genes and 1 miRNA of each cumulus oocyte complex with the corresponding embryo morphology on day 5 (presence or absence of a blastocyst) and blastocyst quality.

Secondary Outcomes

  • Implantation Rate(2 months)

Study Sites (1)

Loading locations...

Similar Trials